End-stage kidney disease and rationing of kidney replacement therapy in the free state province, South Africa: a retrospective study

被引:4
|
作者
Molaoa, Thabang T. [1 ]
Bisiwe, Feziwe B. [1 ]
Ndlovu, Kwazi C. Z. [2 ,3 ]
机构
[1] Univ Free State, Div Nephrol, Dept Internal Med, Bloemfontein, South Africa
[2] Univ Cape Town, Div Nephrol & Hypertens, Cape Town, South Africa
[3] Univ Cape Town, Kidney & Hypertens Res Unit, Cape Town, South Africa
关键词
Incidence rate; End-stage kidney disease; Kidney replacement therapy; Dialysis access; South Africa; SUB-SAHARAN-AFRICA; RENAL-DISEASE; PERITONEAL-DIALYSIS; HEALTH-CARE; TRANSPLANTATION; PREVENTION; PREVALENCE; OUTCOMES; OLDER; HIV;
D O I
10.1186/s12882-021-02387-x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background End-stage kidney disease (ESKD) and the required kidney replacement therapy (KRT) are significant public health challenges for low-and-middle-income countries. The South African government adopted a KRT rationing policy to balance the growing need for KRT and scarce resources. We aimed to describe the epidemiology and KRT access in patients with ESKD referred to the main public sector hospital in the Free State Province, South Africa. Methods A retrospective study of adult patients with ESKD admitted to Universitas Academic Hospital for KRT, was conducted between 1 January 2016 and 31 December 2018. A review of the KRT committee decisions to offer or deny KRT based on the KRT rationing policy of the Free State was undertaken. Demographic information, KRT committee outcomes, laboratory test results, and clinical details were collected from assessment tools, KRT committee meeting diaries, and electronic hospital records. Results Of 363 patients with ESKD referred for KRT access, 96 with incomplete records were excluded and 267 were included in the analysis. Median patient age was 40 (interquartile range, 33-49) years, and male patients accounted for 56.2 % (150/267, p = 0.004) of the cohort. The average annual ESKD incidence was 49.9 (95 % confidence interval [CI], 35.8-64.0) per-million-population. The most prevalent comorbidities were hypertension (42.3 %; 113/267), human immunodeficiency virus (HIV) (28.5 %; 76/267), and diabetes mellitus (19.1 %; 51/267). The KRT access rate was 30.7 % (82/267), with annual KRT incidence rates of 8.05 (95 % CI, 4.98-11.1), 11.5 (95 % CI, 7.83-15.1), and 14.1 (95 % CI, 10.3-18.0) per-million-population in 2016, 2017, and 2018, respectively. Advanced organ dysfunction was the commonest reason recorded for KRT access denial (58.9 %; 109/185). Age (odds ratio [OR], 1.04; 95 % CI, 1.00-1.07; p = 0.024) and diabetes (OR, 5.04; CI, 1.69-15.03; p = 0.004) were independent predictors for exclusion from KRT, while hypertension (OR, 1.80; 1.06-3.04; p = 0.029) independently predicted advanced organ dysfunction resulting in KRT exclusion. Conclusions Non-communicable and communicable diseases, including hypertension, diabetes, and HIV, contributed to ESKD, highlighting the need for improved early prevention strategies to address a growing incidence rate. Two-thirds of ESKD patients were unable to access KRT, with age, diabetes mellitus, and advanced organ dysfunction being significant factors adversely affecting KRT access.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Anemia and Incident End-Stage Kidney Disease
    Saraf, Santosh L.
    Hsu, Jesse Y.
    Ricardo, Ana C.
    Mehta, Rupal
    Chen, Jing
    Chen, Teresa K.
    Fischer, Michael J.
    Hamm, Lee
    Sondheimer, James
    Weir, Matthew R.
    Zhang, Xiaoming
    Wolf, Myles
    Lash, James P.
    KIDNEY360, 2020, 1 (07): : 623 - 630
  • [42] Hypoglycemia in Patients With End-Stage Kidney Disease
    Garibotto, Giacomo
    Russo, Elisa
    Viazzi, Francesca
    Moore, Linda W.
    JOURNAL OF RENAL NUTRITION, 2024, 34 (03) : 187 - 191
  • [43] End-Stage Kidney Disease Without Dialysis
    Moss, Alvin H.
    Armistead, Nancy
    Lupu, Dale
    HEALTH AFFAIRS, 2015, 34 (11)
  • [44] Palliative care in end-stage kidney disease
    Fassett, Robert G.
    Robertson, Iain K.
    Mace, Rose
    Youl, Loren
    Challenor, Sarah
    Bull, Rosalind
    NEPHROLOGY, 2011, 16 (01) : 4 - 12
  • [45] Caring for patients with end-stage kidney disease
    Bates, Jane
    Chitani, Alex
    Dreyer, Gavin
    LANCET, 2015, 386 (9996): : 854 - 855
  • [46] Lupus Nephritis and End-stage Kidney Disease
    Maroz, Natallia
    Segal, Mark S.
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2013, 346 (04): : 319 - 323
  • [47] Cancer Screening in End-Stage Kidney Disease
    Shirazian, Shayan
    Starakiewicz, Piotr
    Latcha, Sheron
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2021, 28 (05) : 502 - +
  • [48] Hematuria and risk for end-stage kidney disease
    Vivante, Asaf
    Calderon-Margalit, Ronit
    Skorecki, Karl
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2013, 22 (03): : 325 - 330
  • [49] Pachydermoperiostosis Presenting With End-Stage Kidney Disease
    Ghai, Hunar K.
    Suresh, Sandhya
    Elumalai, Ram Prasad
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (06)
  • [50] Endotoxin detection in end-stage kidney disease
    Wong, Jonathan
    Jeraj, Hassan
    Vilar, Enric
    Viljoen, Adie
    Farrington, Ken
    JOURNAL OF CLINICAL PATHOLOGY, 2015, 68 (01) : 73 - 78